The life sciences industry has traditionally relied on randomized clinical trials to establish the safety and efficacy of medicines and medical products. Clinical trials remain essential, but they do not always capture what happens when a product reaches a broad and diverse patient population.

This is where Real-World Evidence (RWE) becomes important.

RWE is clinical evidence generated from the analysis of real-world data (RWD). Real-world data can come from routine healthcare activities rather than strictly controlled research environments. It can help organizations understand treatment patterns, outcomes, safety signals, healthcare utilization, and patient experiences in everyday settings.

Clinical trials generally follow carefully defined eligibility criteria, treatment protocols, monitoring schedules, and endpoints. RWE studies can provide insight into populations that may be underrepresented in trials, including patients with multiple health conditions, different demographic characteristics, or varying treatment histories.

The two approaches are not competitors. Instead, clinical trial evidence and RWE can complement each other throughout the product lifecycle.

FDA and EMA Acceptance of RWE for Regulatory Decisions

Regulatory agencies have increasingly recognized the potential of high-quality real-world data and evidence. In the United States, the FDA has established frameworks for using RWE to support certain regulatory decisions involving drugs and biologics, while real-world data and evidence are also relevant to medical device regulatory activities.

In Europe, the European Medicines Agency (EMA) and the broader European regulatory network have also expanded their focus on real-world evidence. Regulatory-grade evidence requires more than simply collecting large amounts of data. The data must be relevant, reliable, appropriately governed, and analyzed using scientifically sound methods.

For pharmaceutical and biotechnology companies, this means an RWE strategy should be designed with regulatory objectives in mind from the beginning. Defining the research question, selecting appropriate data sources, establishing data quality controls, and documenting analytical methods can all influence whether the resulting evidence is useful for regulatory and business decisions.

Types of Real-World Data Sources

An effective EHR / Claims Data Analytics program can combine multiple sources to develop a broader understanding of patients and healthcare outcomes.

Electronic Health Records

Electronic health records contain information generated during routine healthcare encounters. Depending on the system and available permissions, EHR data may include diagnoses, laboratory results, medications, clinical observations, procedures, and treatment histories.

Analyzing EHR data can help organizations evaluate treatment outcomes, patient characteristics, disease progression, and healthcare utilization.

Claims Data

Claims databases provide information related to healthcare services and reimbursement. They can help researchers examine prescription patterns, hospitalizations, procedures, healthcare costs, and treatment journeys across large populations.

Claims data can be particularly useful for understanding how products are used in routine healthcare environments and identifying trends across patient populations.

Patient Registries

Disease and product registries can provide structured longitudinal information about specific patient populations, treatments, devices, or conditions. Registries may support research into long-term outcomes and help fill evidence gaps that are difficult to address through conventional trials alone.

Wearables and Patient-Generated Data

Wearable devices and digital health technologies can generate information about activity, sleep, heart rate, symptoms, and other health-related measures. When appropriately collected, validated, and analyzed, these data sources can provide additional perspectives on patient experiences and outcomes.

The most valuable RWE programs often use multiple complementary data sources rather than relying on one dataset.

How RWE Supports Drug Approvals and Label Expansions

RWE can contribute to evidence generation at different stages of the product lifecycle.

During development, RWE can help organizations understand disease populations, treatment pathways, unmet needs, and potential comparators. These insights can support clinical development planning and help researchers formulate meaningful research questions.

For regulatory submissions, appropriately designed RWE studies may provide supportive evidence for specific regulatory questions. Depending on the product, indication, research design, and regulatory context, RWE can also contribute to evidence supporting expanded indications or label changes.

For example, evidence from routine healthcare settings may help demonstrate how a therapy performs among patient groups that were not fully represented in an initial clinical development program. It may also provide information about treatment effectiveness, utilization, or outcomes over longer periods.

However, RWE should not be treated as a shortcut around rigorous clinical evidence. The strength of an RWE study depends on the research design, data quality, appropriate statistical methodology, control of bias, and transparency of the analysis.

RWE and Post-Market Surveillance & Vigilance Support

Evidence generation does not end after a product receives approval. Once a therapy or medical device enters the broader market, organizations need to continuously monitor safety, effectiveness, utilization, and emerging risks.

This is where Post-Market Surveillance & Vigilance Support becomes particularly important.

Real-world data can help organizations identify potential safety signals and investigate patterns that may not have been apparent in pre-market studies. Healthcare utilization data, EHRs, claims, registries, adverse event information, and other sources can contribute to ongoing surveillance activities.

Post-market evidence can also help companies understand how products are being used in different patient populations and healthcare settings. When potential signals are identified, organizations can conduct additional analyses and determine whether further investigation or regulatory action may be appropriate.

A structured approach to surveillance can support ongoing regulatory readiness while helping organizations maintain a stronger understanding of their products after commercialization.

Building an RWE Strategy From Scratch

Creating an effective RWE program starts with a clearly defined objective. Companies should first determine what business, clinical, or regulatory question they need to answer.

1. Define the Research Question

A precise research question establishes the foundation for the entire project. The objective should identify the population, intervention or exposure, comparator where applicable, outcomes, and timeframe.

2. Select the Right Data Sources

Not every dataset can answer every question. EHR data may be valuable for clinical outcomes, while claims data may offer stronger visibility into healthcare utilization and longitudinal treatment patterns. Registries or patient-generated data may provide additional insights.

3. Assess Data Quality

Data should be evaluated for completeness, consistency, accuracy, timeliness, and relevance. Missing information, inconsistent coding, duplicate records, and other data-quality issues can affect the reliability of findings.

4. Establish an Analytical Framework

The study methodology should account for potential confounding, selection bias, missing data, and other limitations. Statistical methods should be selected according to the research question and characteristics of the available data.

5. Consider Regulatory Expectations

If the evidence may support a regulatory submission, the strategy should incorporate applicable regulatory expectations from the outset. Documentation, traceability, governance, validation, and analytical transparency can become critical components.

6. Connect RWE With the Product Lifecycle

The strongest strategy treats RWE as an ongoing capability rather than a one-time project. Evidence needs can change from clinical development to approval, commercialization, and post-market monitoring.

7. Work With Experienced Life Sciences Specialists

RWE initiatives often require expertise spanning clinical research, data analytics, regulatory requirements, quality, and technology. BioNetwork Consulting supports life sciences organizations with specialized consulting and talent solutions designed around the complexities of regulated environments.

With expertise across life sciences consulting, regulatory compliance, Computer System Validation (CSV), clinical recruitment, and quality-focused operations, BioNetwork Consulting can help organizations develop the capabilities needed to manage increasingly data-driven product lifecycles.

Why RWE Matters for the Future of Life Sciences

Healthcare data is expanding rapidly, and organizations have more opportunities than ever to understand what happens beyond traditional clinical research settings. The challenge is turning that data into reliable, meaningful evidence.

A well-designed Real-World Evidence Strategy can help pharmaceutical, biotech, and medical device organizations make more informed decisions throughout development and commercialization. Combining EHR / Claims Data Analytics with other real-world sources can reveal valuable insights into treatment outcomes and patient populations, while Post-Market Surveillance & Vigilance Support can help organizations maintain visibility into product safety and performance.

BioNetwork Consulting brings regulatory knowledge, technical expertise, and specialized life sciences talent together to help organizations navigate this evolving environment. By connecting compliance, data, clinical operations, and strategic guidance, the company helps clients move toward more informed and sustainable innovation.

Frequently Asked Questions

1. What is a Real-World Evidence strategy?

A Real-World Evidence strategy is a structured plan for collecting, analyzing, and using evidence generated from real-world data to answer clinical, regulatory, commercial, or safety-related questions.

2. What is EHR / Claims Data Analytics used for?

EHR and claims analytics can help organizations study patient populations, treatment patterns, healthcare utilization, outcomes, costs, and other real-world healthcare trends.

3. Can RWE support regulatory decisions?

Yes. Under appropriate circumstances, regulators such as the FDA and EMA can consider real-world evidence. Its usefulness depends on factors including data relevance, reliability, study design, analytical rigor, and the specific regulatory question.

4. How does RWE support post-market surveillance?

RWE can help organizations monitor product use, outcomes, safety trends, and potential signals after commercialization. It can provide additional evidence for ongoing safety and effectiveness assessments.

5. What are common sources of real-world data?

Common sources include EHRs, insurance claims, patient registries, pharmacy data, healthcare databases, wearable devices, digital health technologies, and patient-generated data.

6. Is RWE a replacement for randomized clinical trials?

No. Randomized clinical trials remain a critical source of evidence for demonstrating safety and efficacy. RWE can complement clinical trial findings by providing insights from routine healthcare settings and broader patient populations.

7. Why should companies plan RWE early?

Planning early allows organizations to identify evidence gaps, select appropriate data sources, establish governance, and design studies around potential clinical and regulatory needs rather than trying to collect useful evidence after the fact.

8. How can BioNetwork Consulting help with life sciences initiatives?

BioNetwork Consulting provides life sciences consulting and specialized talent solutions, with expertise in areas including Computer System Validation, regulatory compliance, clinical recruitment, quality, and clinical operations. Its integrated approach helps organizations address complex compliance and operational requirements.